Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

Read more
CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

Read more
CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Read more
Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Read more
Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Read more
Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

Read more
previous arrow
next arrow
  • CD28 targeting
  • How it works

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody

AACR Annual Meeting 2024 - Sara Majocchi -

New publication in MABS 2024

Structural analysis of light chain-driven bispecific antibodies targeting CD47 andPD-L1

TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

Written by Mei Liang Belhumeur on . Posted in News

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body

Read more

LinkedIn